Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Allergy News

3/24/2026
AllergyDry EyeEmergingGene TherapyGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, March 2026
Emerging Companies Pursuing Ophthalmic Indications, March 2026

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

2/27/2026
AllergyBreakingClinical TrialPharmaRegulation
US FDA Gives Green Light to Phase II/III Trial of NexEos Bio’s Vernal Keratoconjunctivitis Candidate
US FDA Gives Green Light to Phase II/III Trial of NexEos Bio’s Vernal Keratoconjunctivitis Candidate

NexEos Bio, of Malvern, Pennsylvania, reported on Feb. 19 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase II/III trial...

1/21/2026
AllergyClinical TrialCornealGene TherapyNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates , January 2026
Clinical Trial Updates for Ophthalmic Candidates , January 2026

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

3/7/2025
AllergyBreakingRegulationRetina
US FDA Approves ANI Pharmaceuticals’ Cortrophin Gel in Prefilled Syringe
US FDA Approves ANI Pharmaceuticals’ Cortrophin Gel in Prefilled Syringe

ANI Pharmaceuticals announced March 3 that the US FDA had approved a prefilled syringe of its purified Cortrophin gel. Among its many indications, the treatment targets acute and chronic inflammato...

12/20/2024
AllergyBreakingChinaDeals
Nicox Reports First Sale of Zerviate in China by Partner Ocumension
Nicox Reports First Sale of Zerviate in China by Partner Ocumension

France’s Nicox reported Dec. 4 that its partner Ocumension Therapeutics had made the first commercial sale of Zerviate (cetirizine ophthalmic solution) 0.24% in China. Zerviate is indicated for ocu...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more